Medizin Spezial Sept2012 engl - ccc.ac.at · joy spending a few hours with doc-tors at the Mini Med...
1
September 2012 Spezi al i i H H EALTH EALTH LITERACY LITERACY P P ATIENTS ATIENTS DEALING DEALING WITH WITH THE THE DISEASE DISEASE Training courses are no substitute for a consultation with a doctor, but they can help. And now more and more patients are going back to school to learn about their illnesses. empowered decision, they need objective, easy-to-understa nd in - formation based on the scientific state of the art. Basic knowledge is the only real protection against misleading or manipulative i nfor- mation,” says Groth. The women’s health centre offers various workshops designed to increase health literacy. A recent EU-wide study by the Ludwig Boltzmann Institute for Ca nc er for Be ginne rs When J. John Cohen, a Canadian- born doctor working in the USA, announced the first Mini Med School lecture over 20 years ago , even he was surprised by the overwhelming level of interest. Within a day, 1,200 p eople from the local area had signed up for his first layman’s course at the Uni- versity of Colorado School of Me- dicine. The idea spread like wild - fire. Today American universities stage more than 70 Mini Med Schools, where lay people can ac- quire basic medical knowledge. Cohen attributes this success to the “five-minute- medicine” effect created by health care systems that are often too strongly geared towards efficiency. “Such systems rarely allow for detailed discussi- ons. Some of my colleagues see 30 patients every day. That barely gives you time to say hello. So it’s hardly surprising that people en - joy spending a few hours with doc- tors at the Mini Med School,” he explains. Gabriela Kornek, head of the Cancer School at the Comprehen - sive Cancer Center in Vienna, con - firms that what patients want most is time for questions and discussi- ons. In Vienna the first school year has just ended. Around 180 parti- cipants, including cancer pati- ents, their relatives and employe- es of medical facilities, attended the lectures to learn more about how cancer starts and how it can be treated. From her own and other people’s experiences in Austria and elsewhere, Kornek knows that “Informed patients take on more personal responsibility and are better at managing their illness”. This maturity also calls for a re - think among doctors. Well-infor- med patients ask more questions and are not easily palmed off with superficial answers, so a proper consultation usually lasts more than five minutes. “On the other hand, if the patients already have some basic knowledge we can make better use of the time we have. Instead of explaining the ba- sic workings of chemotherapy, we can discuss the advantages and di- sadvantages of various treatment options with the patients. And then they can truly have a say in the final decision,” says Kornek. She is convinced that the days when doctors made decisions uni- laterally are over. Boosti ng self-co nfiden ce “It’s really important that doc - tors talk to people in a way they can understand,” says Maria Pflaum of Frauenselbsthilfe nach Krebs, a self-help group for wo - men who have suffered from breast cancer. Cancer patients in particular are often overwhelmed by the technical terms. Pflaum has attended a number of courses over the past 20 years, and has come to the conclusion that knowledge helps to boost self-confidence and courage. Seminars for patients are also increasingly part of international conference schedules. The up - coming European Society for Me- dical Oncology (ESMO) Congress in Vienna will feature lectures and workshops on topics such as pati- ents’ rights and obligations, treat - ment guidelines and quality stan - dards, as well as financial and so - cial issues. Oncologist Heinz Lud - wig, who has been conducting pa- tient seminars at ESMO congres - ses for close to a decade, explains: “Our main aims are to provide in - formation, take away the fear of the unknown and calm any un - founded fears”. In his view, in - creased knowledge enhances self- confidence, resulting in better use of the opportunities offered by mo - dern medicine. Health l iteracy Sylvi a Groth, head of the wo - men’s health c entre in Graz, belie- ves that the ability to look critical- ly at the sources and quality of in - formation is another key aspect in developing health-related know- how. This is the only way to dis - tinguish hard facts from vague promises of a cure or advertising claims for pharmaceuticals. “For patients to make an informed and Health Promotion revealed just how poorly educated Austrians are when it comes to health mat - ters. Nearly a quarter of the inter- viewees had problems understan - ding what their doctor was saying, and almost one-third of them found information in the media difficult to understand. In the view of the study’s author, Jürgen Pelikan, the lessons are clear: “Doctors have to give their pati- ents the chance to take a more ac- tive role. They should not lecture their patients but help them to play a leading role in managing their own health.” Patients are ready to do that, he feels. But for this to happen, they need sufficient con - fidence and assertiveness to ask the right questions and insist on receiving clear answers. A ndrea A A Fried E 7
Transcript of Medizin Spezial Sept2012 engl - ccc.ac.at · joy spending a few hours with doc-tors at the Mini Med...
September 2012 dSpezi dSpezi dal dal dSpezialSpezi dSpezi dal dSpezi d
H HEALTH EALTH LITERACYLITERACY P PATIENTS ATIENTS DEALING DEALING WITH WITH THE THE DISEASEDISEASE
Training courses are no substitute for a consultation with a doctor, but they can help.
And now more and more patients are going back to school to learn
about their illnesses.
empowered decision, they need objective, easy-to-understand in-formation based on the scientific state of the art. Basic knowledge is the only real protection against misleading or manipulative infor-mation,” says Groth. The women’s health centre offers various workshops designed to increase health literacy.
A recent EU-wide study by the Ludwig Boltzmann Institute for
CancCancCa er for Beginners
When J. John Cohen, a Canadian-born doctor working in the USA, announced the first Mini Med School lecture over 20 years ago , even he was surprised by the overwhelming level of interest. Within a day, 1,200 people from the local area had signed up for his first layman’s course at the Uni-versity of Colorado School of Me-dicine. The idea spread like wild-fire. Today American universities stage more than 70 Mini Med Schools, where lay people can ac-quire basic medical knowledge.
Cohen attributes this success to the “five-minute-medicine” effect created by health care systems that are often too strongly geared towards efficiency. “Such systems rarely allow for detailed discussi-ons. Some of my colleagues see 30 patients every day. That barely gives you time to say hello. So it’s hardly surprising that people en-joy spending a few hours with doc-tors at the Mini Med School,” he explains.
Gabriela Kornek, head of the Cancer School at the Comprehen-sive Cancer Center in Vienna, con-firms that what patients want most is time for questions and discussi-ons. In Vienna the first school year has just ended. Around 180 parti-cipants, including cancer pati-ents, their relatives and employe-es of medical facilities, attended the lectures to learn more about how cancer starts and how it can be treated. From her own and otherpeople’s experiences in Austria and elsewhere, Kornek knows that “Informed patients take on more personal responsibility and are better at managing their illness”. This maturity also calls for a re -think among doctors. Well-infor-med patients ask more questions and are not easily palmed off with superficial answers, so a proper consultation usually lasts more than five minutes. “On the other hand, if the patients already have some basic knowledge we can make better use of the time we have. Instead of explaining the ba-sic workings of chemotherapy, we can discuss the advantages and di-sadvantages of various treatment options with the patients. And then they can truly have a say in the final decision,” says Kornek. She is convinced that the days when doctors made decisions uni-laterally are over.
Boosting self-confidence “It’s really important that doc-
tors talk to people in a way they can understand,” says Maria Pflaum of Frauenselbsthilfe nach Krebs, a self-help group for wo-men who have suffered from breast cancer. Cancer patients in particular are often overwhelmed by the technical terms. Pflaum has attended a number of courses over the past 20 years, and has come to the conclusion that knowledge helps to boost self-confidence and courage.
Seminars for patients are also increasingly part of international conference schedules. The up -coming European Society for Me-dical Oncology (ESMO) Congress in Vienna will feature lectures and workshops on topics such as pati-ents’ rights and obligations, treat-ment guidelines and quality stan-dards, as well as financial and so-cial issues. Oncologist Heinz Lud-wig, who has been conducting pa-tient seminars at ESMO congres-ses for close to a decade, explains:
“Our main aims are to provide in-formation, take away the fear of the unknown and calm any un-founded fears”. In his view, in-creased knowledge enhances self-confidence, resulting in better use of the opportunities offered by mo-dern medicine.
Health literacy Sylvia Groth, head of the wo-
men’s health centre in Graz, belie-ves that the ability to look critical-ly at the sources and quality of in-formation is another key aspect in developing health-related know-how. This is the only way to dis-tinguish hard facts from vague promises of a cure or advertising claims for pharmaceuticals. “For patients to make an informed and
Health Promotion revealed just how poorly educated Austrians are when it comes to health mat-ters. Nearly a quarter of the inter-viewees had problems understan-ding what their doctor was saying, and almost one-third of them found information in the media difficult to understand. In the view of the study’s author, Jürgen Pelikan, the lessons are clear: “Doctors have to give their pati-
B E Z A H L T E A N Z E I G E
Engagement für OnkologieDas Hauptaugenmerk bei der Er-
forschung von Krebstherapeutikaverlagert sich immer mehr weg vonchemotherapeutischen Behandlun-gen, die Krebszellen abtöten und dieZellteilung hemmen, hin zu Medika-menten, die Tumorzellen und -ge-webe gezielt auf molekularer Ebeneangreifen. Die Onkologie ist heuteeines der wichtigsten Gebiete, aufdem Daiichi Sankyo Forschungenbetreibt, wobei der Konzern bestrebtist, derartige zielgerichtete moleku-lare Therapeutika in Form von nie-dermolekularen Molekülen und An-tikörpern zu entwickeln.
Die Onkologie ist für Daiichi Sankyonicht neu: 1977 brachte Sankyo eines
der weltweit ersten Mittel für dieKrebstherapie auf den Markt, dasauch heute noch zur Bekämpfungvon Magen- und Dickdarmkrebssowie nicht kleinzelligen Lungen-karzinomen (NSCLC) verwendet wird.Der Biological Response Modifierbasiert auf Xylostromaten und unter-scheidet sich von existierenden che-motherapeutischen Medikamenten.
In den 90er-Jahren wurde eine wei-tere führende Krebstherapie vonDaiichi entwickelt: In Zusammenar-beit mit Yakt Yakt Y ult Honsha entstand Iri-notecan, das noch immer als Stan-dardtherapie für Dickdarmkrebsgilt. Dieser Wirkstoff wurde fürMärkte außerhalb Japans an anderePharmaunternehmen lizenziert.
Daiichi Sankyo ist ein weltweit täti-ges Pharmaunternehmen, in demsich Menschen leidenschaftlich fürErforschung, Entwicklung und Her-stellung innovativer Arzneimittel,die das Leben von Patienten positivverändern, engagieren. Der Konzernselbst entstand im Jahre 2005 durchdie Fusion der beiden japanischenTraditionsunternehmen Daiichi undSankyo und ist derzeit weltweit innahezu 60 Ländern der Erde präsent,u.a. mit 12 Niederlassungen in Europa.
Daiichi Sankyo entwickelt undproduziert innovative Arzneimittel,um wirksame Therapien für bislangunzureichend behandelte Krank-heitsbilder anbieten zu können. Zu-dem verfügt Daiichi Sankyo übereine globale Produktpalette zugelas-sener Arzneimittel zur Behandlungvon Hypertonie, Hyperlipidämie,Thrombose und bakterieller Infeknfeknf ti-onen und konzentriert sich zuneh-mend auf die Entdeckung moderneronkologischer Therapeutika.
Die lange Geschichte von Innovati-onen von Daiichi Sankyo, die mitder Entdeckung von Adrenalin vorüber einem Jahrhundert seinen An-fang nahm, hat viele bedeutendemedizinische Fortschritte hervorge-bracht: Von der Entwicklung der Li-pidsenker aus der Stoffgruppe derStatine bis zur Isolierung von Vita-min B1 und der Entwicklung des ers-ten Glitazons zur Blutzuckerkont-rolle. Heute engagiert sich DaiichiSankyo gleichermaßen in der Erfor-schung moderner Therapien in derOnkologie. Ehrgeiziges Ziel vonDaiichi Sankyo ist es, Arzneimittelzu entwickeln bzw. anzubieten, dieentweder als „Best-in-Class“ geltenoder eine vollständig neue Wirk-stoffklasse begründen.
Daiichi Sankyo investiert umfas-send in die Bereiche Forschung undEntwicklung und damit auch in dieZukunft des Unternehmens. Im Jahr2011 lag das Entwicklungsbudget desUnternehmens bei 1,70 MilliardenEuro. Dies entspricht 19,7 Prozent desNettoumsatzes. Diese Zahl liegt weitüber dem Durchschnittswert derBranche (15–17 Prozent) und zeigtdamit, welche Bedeutung das orga-nische Wachstum für die Geschäfts-strategie von Daiichi Sankyo hat.
Innovation als Tras Tras T dition
Wachsende onkologische PipelineDie Konzentration von Daiichi
Sankyo auf den Bereich Onkologiewird von einem globalen Netzwerkvon Forschungseinrichtungen invier Kernregionen – Japan, den USA,Europa und Indien – gestützt. Die-ses weltweite Netzwerk unterstützteinen raschen Fortschritt in For-schung und Entwicklung. DaiichiSankyo engagiert sich deshalb füreine Erweiterung der Kapazitätenund technischen Ausrüstung imForschungs- und Entwicklungsbe-reich, um damit ein anhaltendesWachstum zu unterstützen. DaiichiSankyo hat seine onkologische Pipe-line durch Partnerschaften und Zu-sammenschlüsse mit anderen füh-renden Firmen in diesem Bereicherweitert, wie ArQule und SeattleGenetics. Im Jahr 2008 erwarb Daii-chi Sankyo U3 Pharma, eine deut-sche Firma mit vielversprechendenAntikörpern in unterschiedlichenEntwicklungsphasen im Bereich derOnkologie. Im Januar 2011 erreichteDaiichi Sankyo in einer Partner-schaft mit ArQule einen wichtigenMeilenstein durch den Start einerPhase-III-Studie mit der neuartigenSubstanz Tivantinib für Patienten,bei denen ein nicht-kleinzelligesBronchialkarzinom (NSCLC) diag-nostiziert wurde und die zuvor eineoder zwei antitumorale Therapienerhalten haben. Durch strategischeZusammenschlüsse und seine damitwachsende onkologische Pipelineträgt Daiichi Sankyo zur Weiterent-wicklung der Krebstherapie bei.
Nähere InforInforInf mationen:[email protected]
Die Historie wissenschaftlicherEntdeckungen begleitet
Daiichi Sankyo seit mehr als100 Jahren.
Daiichi Sankyo investiertumfassend in die BereicheForschung und Entwicklung unddamit auch in die Zukunft desUnternehmens.Foto: Daiichi Sankyo Europe GmbH
ents the chance to take a more ac-tive role.
They should not lecture their patients but help them to play a leading role in managing their own health.” Patients are ready to do that, he feels. But for this to happen, they need sufficient con-fidence and assertiveness to ask the right questions and insist on receiving clear answers.
Andrea Andrea A Fried
E 7
![Rwi sept2012[1]](https://static.fdocuments.in/doc/165x107/554aa560b4c905ec668b4a43/rwi-sept20121.jpg)
